Glaucoma

Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc clinical trial.

SAN DIEGO — Visual field defect on baseline 10-2 testing most effectively predicted subsequent progression on 24-2 testing in patients with glaucoma, Michael J. Sullivan-Mee, OD, FAAO, said at an Academy 2022 press conference.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Ye Elaine Wang, MD, discusses MicroPulse transscleral laser therapy from Iridex.

We are fortunate to have many options for the treatment of glaucoma, including several classes of glaucoma medications, selective laser trabeculoplasty and minimally invasive glaucoma surgery.

CHICAGO — In this Healio Video Perspective from the AAO meeting, I. Paul Singh, MD, shares data about the Glaukos iStent infinite, designed to reduce IOP.

In this exclusive surgical video for Healio/OSN, I. Paul Singh, MD, uses the iStent inject and the iAccess microgoniotomy device to demonstrate a technique for combining stenting and goniotomy for patients with glaucoma.

TC-002, a latanoprost ophthalmic solution, met all primary and secondary endpoints in the phase 3 CLEAR pivotal trial, according to a press release from TearClear.

As a specialty, glaucoma has had no shortage of innovation in recent years.

LAS VEGAS — Corneal hysteresis is an objective measurement that can help clinicians diagnose and manage glaucoma, Nate Lighthizer, OD, FAAO, said at Vision Expo West.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Steven R. Sarkisian, MD, discusses data from a phase 2 trial investigating the iDose sustained-release travoprost implant from Glaukos for the treatment of glaucoma.